Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Gliosarcoma × ficlatuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2 Neoplasms 2 Vascular Diseases 1 Pathologic Processes 1 Paraproteinemias 1 Neoplastic Processes 1 Neoplasms, Plasma Cell 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoproliferative Disorders 1 Lymphoma 1 Lymphatic Diseases 1 Liver Neoplasms 1 Liver Diseases 1 Leukemia, Myeloid, Acute 1 Immunoproliferative Disorders 1 Hemorrhagic Disorders 1 Hematologic Diseases 1 Gliosarcoma 1 Glioblastoma 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Cardiovascular Diseases 1 Carcinoma 1 Blood Protein Disorders 1

Interventions

Temozolomide 42 Radiotherapy 24 Radiation 13 O(6)-benzylguanine 7 Chemotherapy, Adjuvant 7 Irinotecan 6 Carmustine 6 Surgical Procedures, Operative 5 Imatinib Mesylate 5 Erlotinib Hydrochloride 5 sargramostim 4 motexafin gadolinium 4 Radiotherapy, Intensity-Modulated 4 Magnetic Resonance Spectroscopy 4 Hydroxyurea 4 Gene Expression Profiling 4 Radiotherapy, Conformal 3 Immunohistochemistry 3 Genetic Therapy 3 Filgrastim 3 Drug Therapy 3 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3 vandetanib 2 cediranib 2 Specimen Handling 2 Sorafenib 2 Radiosurgery 2 Nivolumab 2 Mass Spectrometry 2 Lenalidomide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01189513 2012-02-20

SCH-900105 in Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡